US Stock MarketDetailed Quotes
ZVSA ZyVersa Therapeutics
- 3.0100
- -0.2500-7.67%
Close Aug 8 16:00 ET
- 2.9400
- -0.0700-2.33%
Post 19:15 ET
2.51MMarket Cap-3P/E (TTM)
3.2700High2.8501Low39.90KVolume3.1600Open3.2600Pre Close119.56KTurnover4.84%Turnover RatioLossP/E (Static)834.90KShares79.800052wk High0.22P/B2.48MFloat Cap2.850152wk Low--Dividend TTM824.57KShs Float8750.0000Historical High--Div YieldTTM12.88%Amplitude2.8500Historical Low2.9960Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
ZyVersa Therapeutics Stock Forum
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
ZyVersa Therapeutics (ZVSA) has chosen obesity and related metabolic complications as the lead indication for its Inflammasome ASC Inhibitor IC 100. This decision is based on the growing global obesity drug market, which reached $24 billion in 2023 and is forecasted to reach up to $131 billion by 2028. Obesity affects over 40% of Am...
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
ZyVersa Therapeutics (ZVSA) announces publication of research demonstrating that its Inflammasome ASC Inhibitor IC 100 restored retinal structure and function in a Retinopathy of Prematurity (ROP) animal model.
The study, published in Angiogenesis, showed that IC 100 suppressed ret...
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a clinical-stage specialty biopharmaceutical company dedicated to developing first-in-class drugs for treating renal and inflammatory diseases, has announced that its Co-Founder, Chairman, Chief Executive Officer, and President, Stephen C. Glover, will be a featured speak...
No comment yet